Pub Date : 2024-01-01Epub Date: 2024-04-17DOI: 10.26502/fjppr.094
Alan Wells, Yadong Wang, Hanshuang Shao, Peri Sohnen, Shivalingappa K Swamynathan
Purpose: Environmentally-triggered dry eye disease (DED) or keratoconjunctivitis sicca (KCS), which constitutes the majority of DED cases, currently is palliatively treated with aqueous replacement solutions that do not target the dysfunction of the mucin and lipid components of tears. We tested whether a peptide that increased goblet cell numbers in a model of scleral chemical injury would also improve tear quality in environmental DED.
Methods: Environmental DED was established by exposing New Zealand white rabbits (8 per group, female) to 20% humidity with rapid air replacement and b.i.d. atropine sulfate eyedrops for 3 weeks prior to test article administration; this continued for the subsequent 3 weeks of testing. Animals were dosed by (A) saline, (B) b.i.d. eyedrop of peptide in saline, (C) b.i.d. eyedrop of peptide in coacervate, or (D) weekly subconjunctival injection of peptide. In vitro, human conjunctival epithelial cells (HCjE) were exposed to TNFα in the presence or absence of peptide to determine inflammatory responsiveness.
Results: The environmental DED was established with both Schirmer and TBUT being reduced at the start of test article; these levels were maintained as low through the testing period. All three treatment regimens increased TBUT approximately 3x to levels greater than prior to desiccation (P < 0.01), with little effect on Schirmer. Corneal haze was present in all eyes after induction, and completely reversed in 36 of 48 eyes across the treatments (P < 0.05). Co-treatment of HCjE with peptide reduced the production of TNFα in response to an inflammatory stimulus.
Conclusions: The treatment of environmental DED/KCS with a peptide that activates CXCR3 improved tear quality and reversed corneal pathology by promoting tear stability and likely dampening the corneal inflammation, while not affecting aqueous volume of the tears.
{"title":"A CXCR3-Activating Peptide Increases Tear Break Up Time and Corrects Corneal haze in a Rabbit Model of Environmental Dry Eye.","authors":"Alan Wells, Yadong Wang, Hanshuang Shao, Peri Sohnen, Shivalingappa K Swamynathan","doi":"10.26502/fjppr.094","DOIUrl":"10.26502/fjppr.094","url":null,"abstract":"<p><strong>Purpose: </strong>Environmentally-triggered dry eye disease (DED) or keratoconjunctivitis sicca (KCS), which constitutes the majority of DED cases, currently is palliatively treated with aqueous replacement solutions that do not target the dysfunction of the mucin and lipid components of tears. We tested whether a peptide that increased goblet cell numbers in a model of scleral chemical injury would also improve tear quality in environmental DED.</p><p><strong>Methods: </strong>Environmental DED was established by exposing New Zealand white rabbits (8 per group, female) to 20% humidity with rapid air replacement and b.i.d. atropine sulfate eyedrops for 3 weeks prior to test article administration; this continued for the subsequent 3 weeks of testing. Animals were dosed by (A) saline, (B) b.i.d. eyedrop of peptide in saline, (C) b.i.d. eyedrop of peptide in coacervate, or (D) weekly subconjunctival injection of peptide. In vitro, human conjunctival epithelial cells (HCjE) were exposed to TNFα in the presence or absence of peptide to determine inflammatory responsiveness.</p><p><strong>Results: </strong>The environmental DED was established with both Schirmer and TBUT being reduced at the start of test article; these levels were maintained as low through the testing period. All three treatment regimens increased TBUT approximately 3x to levels greater than prior to desiccation (P < 0.01), with little effect on Schirmer. Corneal haze was present in all eyes after induction, and completely reversed in 36 of 48 eyes across the treatments (P < 0.05). Co-treatment of HCjE with peptide reduced the production of TNFα in response to an inflammatory stimulus.</p><p><strong>Conclusions: </strong>The treatment of environmental DED/KCS with a peptide that activates CXCR3 improved tear quality and reversed corneal pathology by promoting tear stability and likely dampening the corneal inflammation, while not affecting aqueous volume of the tears.</p>","PeriodicalId":73897,"journal":{"name":"Journal of pharmacy and pharmacology research","volume":"8 2","pages":"23-27"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11086663/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140912807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hashem M. Mansour, Rana A. Kurraz, Ahmed Al Rabii, Khalil I. Masood
Objectives: In this study, we analyzed the data on antimicrobial resistance in the bloodstream . This study aims to evaluate the bacterial resistance in the Gaza Strip and compare with that in other countries. Methods: This study was conducted retrospectively in the Indonesian and Shifa hospitals in the Gaza Strip of Palestine. The isolates were collected from 2020 to 2022 and compared with those from other countries. Chi square test to compare between means. P-value less than 0.05 was considered statistically significant. Results: The incidences of bloodstream infections as well as the resistance against most antibiotics increased. The exceptions were a decreased incidence of P. aeruginosa infection and a decrease in resistance against ceftazidime. Overall, the incidence and resistance of antimicrobials were higher than other countries. Conclusion: These results showed increased trends to bacterial resistance except for ceftazidime. A specialist in clinical microbiology should take an active role in prescribing antibiotics in hospitals based on laboratory and epidemiological data besides clinical experience. Also, antibiotic stewardship should be constructed and activated in our country to, as this will decrease the emergence of resistant strains and decrease the burden
{"title":"Trends in Antimicrobial Resistance in Gaza Strip, 2020–2022: Retrospective Study","authors":"Hashem M. Mansour, Rana A. Kurraz, Ahmed Al Rabii, Khalil I. Masood","doi":"10.26502/fjppr.076","DOIUrl":"https://doi.org/10.26502/fjppr.076","url":null,"abstract":"Objectives: In this study, we analyzed the data on antimicrobial resistance in the bloodstream . This study aims to evaluate the bacterial resistance in the Gaza Strip and compare with that in other countries. Methods: This study was conducted retrospectively in the Indonesian and Shifa hospitals in the Gaza Strip of Palestine. The isolates were collected from 2020 to 2022 and compared with those from other countries. Chi square test to compare between means. P-value less than 0.05 was considered statistically significant. Results: The incidences of bloodstream infections as well as the resistance against most antibiotics increased. The exceptions were a decreased incidence of P. aeruginosa infection and a decrease in resistance against ceftazidime. Overall, the incidence and resistance of antimicrobials were higher than other countries. Conclusion: These results showed increased trends to bacterial resistance except for ceftazidime. A specialist in clinical microbiology should take an active role in prescribing antibiotics in hospitals based on laboratory and epidemiological data besides clinical experience. Also, antibiotic stewardship should be constructed and activated in our country to, as this will decrease the emergence of resistant strains and decrease the burden","PeriodicalId":73897,"journal":{"name":"Journal of pharmacy and pharmacology research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69347890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Roberto I Mota Alvidrez, Gowtham K Annarapu, Amudan J Srinivasan, Zeyu Liu, Hamza O Yazdani, Deidre Nolfi-Donegan, Richard L Simmons, Sruti Shiva, Matthew D Neal
Introduction: Metformin is the most prescribed medication in Diabetes Mellitus(DM). Metformin has shown to decrease mean platelet volume, with promising antiplatelet effects. High doses of Metformin have also been associated with hypercoagulation. We hypothesize that Metformin will protect DM mice from occlusive arterial thrombus formation by altering platelet activation and mitochondrial bioenergetics.
Methods: DM was developed by low dose of Streptozotocin, non-DM (healthy) mice are controls. Either vehicle or Metformin was administered twice daily via oral gavage for 7-days. Ferric chloride (FeCl3) arterial thrombosis and tail bleeding time were performed. Whole blood aggregometry, platelet activation/adhesion and mitochondrial bioenergetics were evaluated.
Results: Metformin decreased susceptibility of DM mice to arterial thrombosis. Platelet bioenergetics show DM mice have increased platelet mitochondrial respiration, but no differences were observed with Metformin treatment. In non-DM (healthy) mice, Metformin modulated ADP-dependent increase in platelet adhesion. Non-DM (healthy) mice, Metformin shortens bleeding time with faster thrombotic occlusion. Metformin also increased platelet mitochondrial maximal respiration and spare respiratory capacity uniquely in non-DM (healthy) mice.
Conclusion: Metformin regulates platelet bioenergetics and ADP-mediated platelet function in DM mice which attenuates susceptibility to arterial thrombosis. Future studies will evaluate clinically relevant doses of Metformin that regulates thrombotic function in diabetic platelets.
{"title":"High Dose of Metformin Decreases Susceptibility to Occlusive Arterial Thrombosis in Diabetic Mice.","authors":"Roberto I Mota Alvidrez, Gowtham K Annarapu, Amudan J Srinivasan, Zeyu Liu, Hamza O Yazdani, Deidre Nolfi-Donegan, Richard L Simmons, Sruti Shiva, Matthew D Neal","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>Metformin is the most prescribed medication in Diabetes Mellitus(DM). Metformin has shown to decrease mean platelet volume, with promising antiplatelet effects. High doses of Metformin have also been associated with hypercoagulation. We hypothesize that Metformin will protect DM mice from occlusive arterial thrombus formation by altering platelet activation and mitochondrial bioenergetics.</p><p><strong>Methods: </strong>DM was developed by low dose of Streptozotocin, non-DM (healthy) mice are controls. Either vehicle or Metformin was administered twice daily via oral gavage for 7-days. Ferric chloride (FeCl3) arterial thrombosis and tail bleeding time were performed. Whole blood aggregometry, platelet activation/adhesion and mitochondrial bioenergetics were evaluated.</p><p><strong>Results: </strong>Metformin decreased susceptibility of DM mice to arterial thrombosis. Platelet bioenergetics show DM mice have increased platelet mitochondrial respiration, but no differences were observed with Metformin treatment. In non-DM (healthy) mice, Metformin modulated ADP-dependent increase in platelet adhesion. Non-DM (healthy) mice, Metformin shortens bleeding time with faster thrombotic occlusion. Metformin also increased platelet mitochondrial maximal respiration and spare respiratory capacity uniquely in non-DM (healthy) mice.</p><p><strong>Conclusion: </strong>Metformin regulates platelet bioenergetics and ADP-mediated platelet function in DM mice which attenuates susceptibility to arterial thrombosis. Future studies will evaluate clinically relevant doses of Metformin that regulates thrombotic function in diabetic platelets.</p>","PeriodicalId":73897,"journal":{"name":"Journal of pharmacy and pharmacology research","volume":"7 4","pages":"192-202"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653203/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136400560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E. Bamgbade, Samson Oluwaseyi Famuyiwa, K. Faloye, Marcus Durojaye Ayoola, Charlotte Mungho Tata, Marthe Carine Djuidje FOTSING, D. Ndinteh
{"title":"Antidiabetic Potential of The Leaf Extracts of Phragmanthera incana (Schum.) Balle Harvested on Albizia lebbeck","authors":"E. Bamgbade, Samson Oluwaseyi Famuyiwa, K. Faloye, Marcus Durojaye Ayoola, Charlotte Mungho Tata, Marthe Carine Djuidje FOTSING, D. Ndinteh","doi":"10.26502/fjppr.069","DOIUrl":"https://doi.org/10.26502/fjppr.069","url":null,"abstract":"","PeriodicalId":73897,"journal":{"name":"Journal of pharmacy and pharmacology research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69347630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Salvatore Chirumbolo, Luigi Valdenassi, Marianno Franzini
I read carefully the recent paper by Fazio et al., on this journal, where the authors widely criticized the approach with which COVID-19 pandemic was addressed by the Italian Government in the dramatic period 2020-2022 [1]. They focused all major concerns on the failure in recommending a sound and reliable home COVID-19 therapy, an issue particularly debated on my own [2-5]. The authors detailed with commendable stubbornness the many shortcomings (and mistakes, as they stated) of the Italian Government Institutions engaged to address public health policy during the COVID-19 pandemic emergency, some of these allegations were addressed also elsewhere [6]. Yet, I wrote this Letter to the Editor because, despite I retrieved some scientific convergence in the tale exposed by the colleagues, I would like to raise doubts about the “alternative” the authors make available as a convenient proposal, i.e., “freedom of cure” rather than “Government guidelines”. First, naming as a “Government’s guideline” a draft focused on a trivial, commonly used painkiller to address SARS-CoV2 infection at the earliest, is ridiculous.
{"title":"COVID-19 Home Therapy. It Has Never Been a Matter of Freedom of Cure","authors":"Salvatore Chirumbolo, Luigi Valdenassi, Marianno Franzini","doi":"10.26502/fjppr.081","DOIUrl":"https://doi.org/10.26502/fjppr.081","url":null,"abstract":"I read carefully the recent paper by Fazio et al., on this journal, where the authors widely criticized the approach with which COVID-19 pandemic was addressed by the Italian Government in the dramatic period 2020-2022 [1]. They focused all major concerns on the failure in recommending a sound and reliable home COVID-19 therapy, an issue particularly debated on my own [2-5]. The authors detailed with commendable stubbornness the many shortcomings (and mistakes, as they stated) of the Italian Government Institutions engaged to address public health policy during the COVID-19 pandemic emergency, some of these allegations were addressed also elsewhere [6]. Yet, I wrote this Letter to the Editor because, despite I retrieved some scientific convergence in the tale exposed by the colleagues, I would like to raise doubts about the “alternative” the authors make available as a convenient proposal, i.e., “freedom of cure” rather than “Government guidelines”. First, naming as a “Government’s guideline” a draft focused on a trivial, commonly used painkiller to address SARS-CoV2 infection at the earliest, is ridiculous.","PeriodicalId":73897,"journal":{"name":"Journal of pharmacy and pharmacology research","volume":"155 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135844056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Francesca Di Mario, Eleonora Galosi, Paolo Greco, Caterina Maccari, Brenda Menegazzo, Teresa Coccini, Elisa Roda, Enrico Fiaccadori
Pregabalin is an anti-epileptic drug which also represents one of the most frequently prescribed medications for neuropathic pain management worldwide. Moreover, in recent years its use has widely increased also in critically ill patients in the setting of multimodal analgesia. Commonly available as capsules and oral solution, it is characterized by a predominant kidney elimination. Consequently, in patients with kidney failure posology adjustments are needed. According to the pharmacokinetic parameters (low molecular weight and volume of distribution, negligible protein binding), pregabalin is expected to undergo a significant extracorporeal clearance, which should be taken into account when one of the different Kidney Replacement Therapy (KRT) modalities is required for Acute Kidney Injury (AKI). The case of a critically ill patient with AKI undergoing Therapeutic Drug Monitoring of Pregabalin in course of Continuous, Prolonged Intermittent KRT (CKRT and PIKRT, respectively), and conventional intermittent hemodialysis (IHD) is presented here for the first time.
{"title":"Therapeutic Drug Monitoring of Pregabalin in a Critically ill Patient with Acute Kidney Injury undergoing Continuous, Prolonged Intermittent, and Intermittent Kidney Replacement Therapy","authors":"Francesca Di Mario, Eleonora Galosi, Paolo Greco, Caterina Maccari, Brenda Menegazzo, Teresa Coccini, Elisa Roda, Enrico Fiaccadori","doi":"10.26502/fjppr.086","DOIUrl":"https://doi.org/10.26502/fjppr.086","url":null,"abstract":"Pregabalin is an anti-epileptic drug which also represents one of the most frequently prescribed medications for neuropathic pain management worldwide. Moreover, in recent years its use has widely increased also in critically ill patients in the setting of multimodal analgesia. Commonly available as capsules and oral solution, it is characterized by a predominant kidney elimination. Consequently, in patients with kidney failure posology adjustments are needed. According to the pharmacokinetic parameters (low molecular weight and volume of distribution, negligible protein binding), pregabalin is expected to undergo a significant extracorporeal clearance, which should be taken into account when one of the different Kidney Replacement Therapy (KRT) modalities is required for Acute Kidney Injury (AKI). The case of a critically ill patient with AKI undergoing Therapeutic Drug Monitoring of Pregabalin in course of Continuous, Prolonged Intermittent KRT (CKRT and PIKRT, respectively), and conventional intermittent hemodialysis (IHD) is presented here for the first time.","PeriodicalId":73897,"journal":{"name":"Journal of pharmacy and pharmacology research","volume":"2014 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135212713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: An association between hypoglycemia and arterial hypertension has been proposed. Here, we report a case of an elderly type-2 diabetic presenting with hypertensive crisis, which improved after insulin-dose reduction.
{"title":"Correction of Over-Dosed Insulin in a Type-2- Diabetic Led to a Better Control of Glycemia and Arterial Hypertension: A Case Report","authors":"Abimbola Abobarin-Adeagbo, Torsten Kraya, Matthias Girndt, Rainer Ullrich Pliquett","doi":"10.26502/fjppr.087","DOIUrl":"https://doi.org/10.26502/fjppr.087","url":null,"abstract":"Introduction: An association between hypoglycemia and arterial hypertension has been proposed. Here, we report a case of an elderly type-2 diabetic presenting with hypertensive crisis, which improved after insulin-dose reduction.","PeriodicalId":73897,"journal":{"name":"Journal of pharmacy and pharmacology research","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135508565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Neveen A. Elnozahi, Esraa A. Abdelaziz, Maged W. Helmy, Azza E. Bistawroos
Triple negative breast cancer is the most aggressive subtype of breast cancer, and its treatment is limited. The effect of abemaciclib and /or sodium butyrate on MDA-MB-231 triple negative breast cancer cells was investigated. The IC50 for the growth inhibitory effects of abemaciclib, sodium butyrate, and their combination were 14.55 μM, 7.08 mM, and 3.743 mM, respectively. The combination showed a synergistic interaction with a decrease in IC50 to 2.55 μM abemaciclib and 3.74 mM butyrate. Three replicates of four groups of cancer cells were treated for 48 hr with the IC50 of abemaciclib, butyrate or their high or low dose combinations. A fifth group was treated with complete medium and served as the control. Cell migration, protein expression levels of cyclin D1, E2F2 transcription factor, phosphorylated AKT, nuclear factor kappa B (NF-κB), cyclin dependent kinase-2 (CDK2), retinoblastoma (Rb), p16INK4a, p53 and mRNA levels of CDK2, p16INK4a and p53 were assessed in all treated groups. Combination treatment with abemaciclib and butyrate showed a significant attenuation of cell metastasis. The combination treatment was associated with a decrease in E2F2, CDK2, and NF-κB protein levels together with attenuation in AKT phosphorylation level. The combination also showed an elevation in Rb, and p16INK4a, together with a reversal of DNA hypo-methylated state. Although abemaciclib monotherapy failed to alter cyclin D1 or p53 levels, the combination significantly reduced cyclin D1 level together with an increase in P53 level. In conclusion, combining butyrate with abemaciclib augmented its antiproliferative and antimetastatic effects and induced apoptotic activity
{"title":"Modulatory Effect of Sodium Butyrate on the Anticancer Activity of Abemaciclib in MDA-MB-231 Human Breast Cancer Cells","authors":"Neveen A. Elnozahi, Esraa A. Abdelaziz, Maged W. Helmy, Azza E. Bistawroos","doi":"10.26502/fjppr.071","DOIUrl":"https://doi.org/10.26502/fjppr.071","url":null,"abstract":"Triple negative breast cancer is the most aggressive subtype of breast cancer, and its treatment is limited. The effect of abemaciclib and /or sodium butyrate on MDA-MB-231 triple negative breast cancer cells was investigated. The IC50 for the growth inhibitory effects of abemaciclib, sodium butyrate, and their combination were 14.55 μM, 7.08 mM, and 3.743 mM, respectively. The combination showed a synergistic interaction with a decrease in IC50 to 2.55 μM abemaciclib and 3.74 mM butyrate. Three replicates of four groups of cancer cells were treated for 48 hr with the IC50 of abemaciclib, butyrate or their high or low dose combinations. A fifth group was treated with complete medium and served as the control. Cell migration, protein expression levels of cyclin D1, E2F2 transcription factor, phosphorylated AKT, nuclear factor kappa B (NF-κB), cyclin dependent kinase-2 (CDK2), retinoblastoma (Rb), p16INK4a, p53 and mRNA levels of CDK2, p16INK4a and p53 were assessed in all treated groups. Combination treatment with abemaciclib and butyrate showed a significant attenuation of cell metastasis. The combination treatment was associated with a decrease in E2F2, CDK2, and NF-κB protein levels together with attenuation in AKT phosphorylation level. The combination also showed an elevation in Rb, and p16INK4a, together with a reversal of DNA hypo-methylated state. Although abemaciclib monotherapy failed to alter cyclin D1 or p53 levels, the combination significantly reduced cyclin D1 level together with an increase in P53 level. In conclusion, combining butyrate with abemaciclib augmented its antiproliferative and antimetastatic effects and induced apoptotic activity","PeriodicalId":73897,"journal":{"name":"Journal of pharmacy and pharmacology research","volume":"13 5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69347635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Impact of Early Palliative Care on End of life in patients with Advanced Biliary Tract Cancer","authors":"M. Miralles, Marie Muller, C. Borg, S. Manfredi","doi":"10.26502/fjppr.065","DOIUrl":"https://doi.org/10.26502/fjppr.065","url":null,"abstract":"","PeriodicalId":73897,"journal":{"name":"Journal of pharmacy and pharmacology research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69347539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
W. Qiu, Shouli Yuan, Robbie Kelleher, Lina Sun, Wei Chen, H. Sheridan, Junying Liu, W. Lv
{"title":"A Systems Pharmacology Approach, Using Molecular Docking and Dynamics Simulation, to Unlock Potential New Therapies for Alzheimer’s Disease: A Case Study of Cinnamon Species","authors":"W. Qiu, Shouli Yuan, Robbie Kelleher, Lina Sun, Wei Chen, H. Sheridan, Junying Liu, W. Lv","doi":"10.26502/fjppr.074","DOIUrl":"https://doi.org/10.26502/fjppr.074","url":null,"abstract":"","PeriodicalId":73897,"journal":{"name":"Journal of pharmacy and pharmacology research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69347884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号